Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

Delayed Quote. Delayed  - 07/29 10:14:59 pm
9.51 USD   +0.42%
07/28 ARIAD PHARMACEU : beats 2Q profit forecasts
07/28 ARIAD PHARMACEU : Reports Second Quarter and First Half 2016 Financi..
07/07 ARIAD PHARMACEU : Biotechnology Equities Under the Scanner - Exelixi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ariad Pharmaceuticals, Inc. : ARIAD Announces Completion of Public Offering

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/29/2013 | 10:20pm CEST

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.60 per share. In addition, the underwriters have exercised an option to purchase an additional 1,182,893 shares at $19.60 per share to cover over-allotments. The total gross proceeds from the offering are approximately $323 million. Net proceeds to ARIAD are approximately $310 million after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies & Company, Inc. acted as joint book-running managers and underwriters for the offering. BMO Capital Markets, Leerink Swann LLC, RBC Capital Markets, LLC and UBS Investment Bank acted as co-managers for the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 866-803-9204), the offices of Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number 631-274-2806), or the offices of Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About ARIAD

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. For more information about ARIAD, visit the company's website at www.ariad.com.

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
07/28 ARIAD PHARMACEUTICALS : beats 2Q profit forecasts
07/28 ARIAD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regul..
07/28 ARIAD PHARMACEUTICALS : Reports Second Quarter and First Half 2016 Financial Res..
07/22 ARIAD PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders,..
07/07 ARIAD PHARMACEUTICALS : Announces Webcast of Its Annual Stockholders Meeting
07/07 ARIAD PHARMACEUTICALS : Biotechnology Equities Under the Scanner - Exelixis, Nov..
07/05 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Second Quarter 2016 Financ..
06/30 ARIAD PHARMACEUTICALS : Initiates Submission of New Drug Application for Brigati..
06/30 ARIAD PHARMACEUTICALS : Announces Distribution Agreements for Iclusig® in Latin ..
06/24 ARIAD PHARMACEUTICALS : Announces Webcast of Its Annual Stockholders Meeting
More news
Sector news : Bio Therapeutic Drugs
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
07/29 What Should Ariad Shareholders Watch For Heading Towards The End Of The Year?
07/28 ARIAD Pharmaceuticals' (ARIA) CEO Paris Panayiotopoulos on Q2 2016 Results - ..
07/28 ARIAD Pharmaceuticals revenues up 133% in Q2
07/28 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2016 193 M
EBIT 2016 -120 M
Net income 2016 -55,1 M
Debt 2016 224 M
Yield 2016 139%
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 10,6x
EV / Sales 2017 8,46x
Capitalization 1 821 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 10,1 $
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Frank G. Haluska Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..52.16%1 821
AMGEN, INC.5.98%129 232
GILEAD SCIENCES, INC.-21.46%105 840
CELGENE CORPORATION-6.32%86 960
REGENERON PHARMACEUTIC..-21.69%44 671
VERTEX PHARMACEUTICALS..-22.91%23 993
More Results